Investors of Amarin (AMRN), the maker of high triglycerides treatment, Vascepa, have had a rough 2020. Despite a strong rebound in April, the …
If after seeing Amarin (AMRN) stock tumble 35% over the past year, you consoled yourself with the knowledge that “at least it can’t …
Today, Amarin (AMRN) investors are scratching their heads as to why the stock tumbled following the announcement that the FDA has approved the …
Buoyed by optimism over the label expansion of Amarin’s (AMRN) flagship drug, Vascepa, the fish oil drug maker’s stock has run off to …
Get in here before November 14, 2019. On this date an FDA Advisory Committee (AdCom) is scheduled to meet to discuss Amarin’s (AMRN) …
Wall Street loves growth stocks — and for good reason. In 2018, according to Bank of America, “growth” oriented mutual funds outperformed “value” …
One week ago, Stifel analyst Derek Archila reiterated his “buy” rating on anti-cholesterol drugmaker Amarin (AMRN). He did this partly because he liked …
In an acronym-heavy update, Stifel analyst Derek Archila reiterated his “buy” rating on anti-cholesterol drugmaker Amarin Corporation (AMRN) following the company’s Q2 earnings …
With primary care clinicians playing an ever-increasing role in the management of diabetes, staying on top of new developments in the American Diabetes …
Do you have high cholesterol? Investors in Amarin (AMRN) kind of hope that you do — but ideally, not too high.